| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cytochalasin C targets actin filaments by binding to the barbed (fast-growing) ends of actin filaments. This binding inhibits actin polymerization and blocks the elongation of actin filaments. By disrupting actin filament dynamics, the compound interferes with cytoskeletal organization. One cytochalasin molecule binds to one actin filament, effectively capping the filament end and preventing further monomer addition. This mechanism of action affects multiple actin-dependent cellular processes.
|
|---|---|
| ln Vitro |
In vitro, Cytochalasin C inhibits actin polymerization at a concentration of 10 uM. It promotes rapid initial filament formation but ultimately reduces steady-state polymerization. The compound is cytotoxic to HeLa cells with an IC₅0 of less than 0.32 ug/ml. Previous studies have described the results of actin assembly assays in the presence of various cytochalasins. By disrupting actin dynamics, Cytochalasin C interferes with cell growth, movement, phagocytosis, degranulation, and secretion.
|
| ln Vivo |
In vivo studies of Cytochalasin C are limited, as it is primarily used as a research tool in cell-based assays. As a fungal metabolite and mycotoxin, it can change cellular morphology, inhibit cellular processes such as cell division, and cause cells to undergo apoptosis. The compound's ability to disrupt actin cytoskeleton makes it potentially useful for studying actin-related physiological processes in animal models. However, its in vivo applications are constrained by its cytotoxicity and lack of target specificity. Further studies are needed to evaluate its potential in vivo.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, Cytochalasin C is evaluated using actin polymerization assays. The compound is incubated with purified actin monomers (G-actin) at various concentrations in polymerization buffer containing salts and ATP. Actin polymerization is monitored by measuring the increase in fluorescence of pyrene-labeled actin or by following the increase in absorbance at 350 nm due to light scattering. The rate and extent of polymerization are measured to determine the inhibitory effect. IC₅0 values are calculated from dose-response curves. Standard assay conditions include physiological ionic strength and temperature.
|
| Cell Assay |
For in vitro cellular experiments, Cytochalasin C is tested in various cell lines to evaluate its effects on actin cytoskeleton and actin-dependent cellular functions. Cells are cultured in appropriate media and treated with various concentrations of the compound (typically ranging from nanomolar to micromolar). Actin filament organization is assessed by fluorescent staining with phalloidin and visualized by fluorescence microscopy. Cell morphology, migration, phagocytosis, and cytokinesis are evaluated. Cell viability is assessed using standard assays such as MTT. The compound's effects on actin dynamics and cellular processes are quantified.
|
| Animal Protocol |
For in vivo animal experiments, Cytochalasin C can be administered to animals via various routes including intraperitoneal injection or intravenous injection. However, as a cytotoxic fungal metabolite, its in vivo use is limited. The compound could be used in studies investigating the role of actin in physiological processes such as tissue development, wound healing, and immune cell function. Typical doses would need to be carefully determined to balance efficacy and toxicity. Animal studies should follow appropriate ethical guidelines. Further studies are needed to establish standardized protocols for in vivo administration.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cytochalasin C are not extensively characterized in the literature. As a fungal metabolite with a molecular weight of 507.62, it is expected to have moderate lipophilicity and tissue distribution. The compound is cell-permeable, facilitating its uptake into cells. When administered systemically, it would likely be distributed to various tissues and metabolized by liver enzymes. Its half-life in circulation would depend on its stability and clearance mechanisms. Further pharmacokinetic studies would be needed to fully characterize its absorption, distribution, metabolism, and excretion profile in vivo.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cytochalasin C indicate that it is cytotoxic to HeLa cells with an IC₅0 of less than 0.32 ug/ml. As a mycotoxin, it can change cellular morphology, inhibit cellular processes such as cell division, and cause cells to undergo apoptosis. The compound's toxicity is primarily attributed to its disruption of the actin cytoskeleton, which is essential for numerous cellular functions. Standard toxicological assessments would include cytotoxicity screening in various cell lines and acute toxicity studies in animal models. As with all research chemicals, appropriate safety precautions should be taken when handling Cytochalasin C.
|
| References |
|
| Additional Infomation |
Cytochalasin C is a research compound used to study actin polymerization and cytoskeletal dynamics. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is a cell-permeable fungal metabolite that inhibits actin polymerization by binding to the barbed ends of actin filaments. It interferes with diverse cellular processes including cell growth, movement, phagocytosis, degranulation, and secretion. Cytochalasin C is widely used in cell biology research as a tool for studying actin-dependent processes.
|
| Molecular Formula |
C30H37NO6
|
|---|---|
| Molecular Weight |
507.61788
|
| Exact Mass |
507.262
|
| CAS # |
22144-76-9
|
| PubChem CID |
5836594
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
714.3±60.0 °C at 760 mmHg
|
| Melting Point |
260-264ºC
|
| Flash Point |
385.8±32.9 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.602
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
37
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C[C@@H]1CC=C[C@H]2[C@H](O)C(C)=C(C3[C@@H](NC([C@@]23[C@@H](OC(C)=O)C=C[C@](C1=O)(O)C)=O)CC4=CC=CC=C4)C
|
| InChi Key |
NAIODHJWOHMDJX-WISUYLHISA-N
|
| InChi Code |
InChI=1S/C30H37NO6/c1-17-10-9-13-22-26(33)19(3)18(2)25-23(16-21-11-7-6-8-12-21)31-28(35)30(22,25)24(37-20(4)32)14-15-29(5,36)27(17)34/h6-9,11-15,17,22-26,33,36H,10,16H2,1-5H3,(H,31,35)/b13-9+,15-14-
|
| Chemical Name |
[(3Z,9E)-16-benzyl-5,12-dihydroxy-5,7,13,14-tetramethyl-6,18-dioxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9,13-trien-2-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9700 mL | 9.8499 mL | 19.6998 mL | |
| 5 mM | 0.3940 mL | 1.9700 mL | 3.9400 mL | |
| 10 mM | 0.1970 mL | 0.9850 mL | 1.9700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
